Tumor cell antigens on AML cells and select solid tumors

Tumor cell antigens on AML cells and select solid tumors refers to a broad category of surface proteins and intracellular molecules that are overexpressed or aberrantly expressed on acute myeloid leukemia (AML) blasts and certain solid tumor types. These antigens, which include well-characterized targets such as CD33, CD123 (IL-3Rα), CLL-1 (CLEC12A), and B7-H3 (CD276), serve as the basis for targeted immunotherapies including antibody-drug conjugates (ADCs), bispecific T-cell engagers (TCEs), and chimeric antigen receptor (CAR) T-cell therapies. Their biological roles often involve promoting cell survival, proliferation, and immune evasion within the tumor microenvironment. In AML, these antigens are frequently shared with normal hematopoietic progenitor cells, leading to therapeutic challenges such as myelosuppression. Conversely, their expression on select solid tumors, such as non-small cell lung cancer or pediatric sarcomas, allows for the development of cross-indication therapeutic strategies. Monitoring the expression levels of these antigens is critical for patient selection and assessing the risk of antigen escape or on-target, off-tumor toxicities.

Other names

Tumor-associated antigensTAAsAML-associated antigensLeukemia-associated antigensLAAs